Skip to main navigation
Skip to search
Skip to main content
University of Kentucky Home
LOGIN & Help
Home
Research units
Researchers
Projects & Grants
Research Output
Facilities & Equipment
Honors & Awards
Activities
Search by expertise, name or affiliation
A Randomized, Multi-Center, Open-Label, Active-Controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) versus Octreotide LAR or Lanreotide ATG in Patients with Gastroenteropancreatic
Anthony, Lowell
(PI)
Markey Cancer Center / Cancer Research Priority Initiative
Overview
Grants and Contracts Details
Status
Finished
Effective start/end date
12/2/21
→
8/21/24
Funding
Fortrea Incorporated:
$26,300.00
View all
View less